Tonix Pharmaceuticals Holding Corp. Annual report [Section 13 and 15(d), not S-K Item 405]

Annual report [Section 13 and 15(d), not S-K Item 405]

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
Dec. 31, 2024
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 19 – SUBSEQUENT EVENTS On February 3, 2025, the Company paid $9.6 million as a result of a pay-off of its outstanding loan facility. The pay-off amount paid by the Company in connection with the termination of the Loan Agreement was pursuant to a pay-off letter and includes a prepayment fee of $1.0 million in accordance with the terms and provisions of the Loan Agreement. On February 20, 2025, the Company received a letter from The NASDAQ Stock Market LLC stating that because the Company’s shares had a closing bid price at or above $1.00 per share for a minimum of 10 consecutive business days, the Company’s stock had regained compliance with the minimum bid price requirement of $1.00 per share for continued listing on the NASDAQ Capital Market, as set forth in NASDAQ Listing Rule 5550(a)(2), and that the matter is now closed. On February 25, 2025, the Company granted options to purchase an aggregate of 449,708 shares of the Company’s common stock to employees with an exercise price of $8.05. Additionally, the Company granted options to purchase 221,558 shares of the Company’s common stock to certain employees with an exercise price of $10.06. Subsequent to December 31, 2024, the Company has sold 2.3 million shares of common stock under the Sales Agreement, for net proceeds of approximately $46.3 million. Subsequent to December 31, 2024, the Company repurchased 250,000 of its shares of common stock outstanding under the 2024 share repurchase program at prices ranging from $9.98 to $14.33 per share for a gross aggregate cost of approximately $3.0 million.

SUBSEQUENT EVENTS

12 Months Ended

Dec. 31, 2024

NOTE 19 – SUBSEQUENT EVENTS

On February 3, 2025, the Company paid $9.6 million as a result of a pay-off of its outstanding loan facility. The pay-off amount paid by the Company in connection with the termination of the Loan Agreement was pursuant to a pay-off letter and includes a prepayment fee of $1.0 million in accordance with the terms and provisions of the Loan Agreement.

On February 20, 2025, the Company received a letter from The NASDAQ Stock Market LLC stating that because the Company’s shares had a closing bid price at or above $1.00 per share for a minimum of 10 consecutive business days, the Company’s stock had regained compliance with the minimum bid price requirement of $1.00 per share for continued listing on the NASDAQ Capital Market, as set forth in NASDAQ Listing Rule 5550(a)(2), and that the matter is now closed.

On February 25, 2025, the Company granted options to purchase an aggregate of 449,708 shares of the Company’s common stock to employees with an exercise price of $8.05. Additionally, the Company granted options to purchase 221,558 shares of the Company’s common stock to certain employees with an exercise price of $10.06.

Subsequent to December 31, 2024, the Company has sold 2.3 million shares of common stock under the Sales Agreement, for net proceeds of approximately $46.3 million.

Subsequent to December 31, 2024, the Company repurchased 250,000 of its shares of common stock outstanding under the 2024 share repurchase program at prices ranging from $9.98 to $14.33 per share for a gross aggregate cost of approximately $3.0 million.